Dynavax 17.12.2008 zu 0.6€ gekauft
Seite 4 von 4 Neuester Beitrag: 25.04.21 00:49 | ||||
Eröffnet am: | 17.12.08 23:52 | von: _bbb_ | Anzahl Beiträge: | 94 |
Neuester Beitrag: | 25.04.21 00:49 | von: Dianaovfya | Leser gesamt: | 20.587 |
Forum: | Hot-Stocks | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | > |
Hör dir mal bitte den webcast an. Partnerships sind von essentieller Bedeutung und sie sind weiter auf der Suche nach geeigneten Kooperationen. Dies sagt er mehrmals, das erste (?) mal jedoch bei 16:35.
Ab 17:00 EMA 120-Questions;
ab 20:22 dann wieder Heplisav - das interessante Zeug.
-> 21:19 "final draft protocol is in with the fda and they are due to have that back to us before the end of this month"
(entschuldigt die möglichen Fehler, bin kein Muttersprachler);
ab 22:00 partnerships with AZ and GSK moving forward;
LG, biotech
Ab 17:00 EMA 120-Questions;
ab 20:22 dann wieder Heplisav - das interessante Zeug.
-> 21:19 "final draft protocol is in with the fda and they are due to have that back to us before the end of this month"
(entschuldigt die möglichen Fehler, bin kein Muttersprachler);
ab 22:00 partnerships with AZ and GSK moving forward;
LG, biotech
Merck may eye vaccine makers
Merck is no stranger to making huge deals to acquire intriguing pipelines, and it is currently bleeding money from lost patent protections. So I fully expect them to be aggressive in going after ways to stop the bleeding.
The good news is that there are some very compelling buyout possibilities in the vaccine space for Merck this year. One of Merck's core businesses is vaccines, and as such, I think there are three companies that could fit the bill.
1. Dynavax (DVAX) - Heplisav is an experimental Hep B vaccine that could be approved in Europe this year and in the U.S. in 2016. Merck already has a recombinant Hep B vaccine, so they are no strangers to this market opportunity.
2. Inovio Pharmaceuticals (INO) - VGX-3100 is a cervical dysplasia vaccine candidate set to report mid-stage results by mid-2014. Merck is the maker of the infamous Gardasil, so there would be an interesting synergy created with a merger.
3. Novavax (NVAX) - developing state-of-the-art influenza vaccines that would compete directly against Merck's Afluria.
Merck is no stranger to making huge deals to acquire intriguing pipelines, and it is currently bleeding money from lost patent protections. So I fully expect them to be aggressive in going after ways to stop the bleeding.
The good news is that there are some very compelling buyout possibilities in the vaccine space for Merck this year. One of Merck's core businesses is vaccines, and as such, I think there are three companies that could fit the bill.
1. Dynavax (DVAX) - Heplisav is an experimental Hep B vaccine that could be approved in Europe this year and in the U.S. in 2016. Merck already has a recombinant Hep B vaccine, so they are no strangers to this market opportunity.
2. Inovio Pharmaceuticals (INO) - VGX-3100 is a cervical dysplasia vaccine candidate set to report mid-stage results by mid-2014. Merck is the maker of the infamous Gardasil, so there would be an interesting synergy created with a merger.
3. Novavax (NVAX) - developing state-of-the-art influenza vaccines that would compete directly against Merck's Afluria.
Dynavax Technologies (DVAX) is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Its main product is Heplisav which is meant to treat Hepatitis B and is in Phase III trials.
DVAX has risen more than 70% since its lows in November but is still selling for less than half its levels earlier in 2013. Not surprisingly for a biotech concern, three insiders bought over $300K worth of new shares at the end of October almost exactly at the stock's recent bottom.
Analysts are high on this ~$2 a share stock. The four analysts that cover the stock have a $4.50 median price target on DVAX. Price targets range from $3 to $6 a share. Dynavax has partnerships with GlaxoSmithKline (GSK) and AstraZeneca (AZN) for the development of its candidates, and will receive milestone payments.
The company has five candidates in its pipeline, where three are currently running clinical trials. Dynavax has over $75mm of net cash on the balance sheet and has a market capitalization just a tad over $500mm.
DVAX has risen more than 70% since its lows in November but is still selling for less than half its levels earlier in 2013. Not surprisingly for a biotech concern, three insiders bought over $300K worth of new shares at the end of October almost exactly at the stock's recent bottom.
Analysts are high on this ~$2 a share stock. The four analysts that cover the stock have a $4.50 median price target on DVAX. Price targets range from $3 to $6 a share. Dynavax has partnerships with GlaxoSmithKline (GSK) and AstraZeneca (AZN) for the development of its candidates, and will receive milestone payments.
The company has five candidates in its pipeline, where three are currently running clinical trials. Dynavax has over $75mm of net cash on the balance sheet and has a market capitalization just a tad over $500mm.
Es gab laut SA-Artikel 3 Insider Buys und siehe da, Yahoo Finance listet sie nicht unter Insider Transactions, sondern Insider Roster:
1.
KISNER DANIEL L
Director Purchase§
Oct 30, 2013 15,000
2.
ORONSKY ARNOLD L
Director Purchase§
Oct 30, 2013 375,055
3.
PHILLIPS PEGGY V
Director Purchase§
Oct 30, 2013 138,023
Alles in allem 528078 Aktien zum Preis von etwa 1.27 USD (30.10.2013). Macht dann etwa 670659,06 USD! Das nenne ich einen dicken batzen zum Schnäppchenpreis.
biotech
1.
KISNER DANIEL L
Director Purchase§
Oct 30, 2013 15,000
2.
ORONSKY ARNOLD L
Director Purchase§
Oct 30, 2013 375,055
3.
PHILLIPS PEGGY V
Director Purchase§
Oct 30, 2013 138,023
Alles in allem 528078 Aktien zum Preis von etwa 1.27 USD (30.10.2013). Macht dann etwa 670659,06 USD! Das nenne ich einen dicken batzen zum Schnäppchenpreis.
biotech
http://finance.yahoo.com/q/ao?s=DVAX+Analyst+Opinion
Auch unter Analyst Rating Network nachzulesen (gute Quelle):
http://www.analystratings.net/stocks/NASDAQ/DVAX/
Mir würde am Anfang ne glatte drei reichen, aber würd bei 4,5,6 auch nicht meckern...
Auch unter Analyst Rating Network nachzulesen (gute Quelle):
http://www.analystratings.net/stocks/NASDAQ/DVAX/
Mir würde am Anfang ne glatte drei reichen, aber würd bei 4,5,6 auch nicht meckern...
Warten wir eben auf die morgige Eröffnung in den USA. Ich erwarte was schönes... (Nur meine Meinung)
LG, biotech
LG, biotech
zwar zugegebenermaßen sehr langsam aber ab morgen wird's in den usa wohl weiter abgehen. ask ist dort 2.19
Die Aktie ist doch zumindest etwas ins Bewusstsein gerückt.
Auf YaFi's Market Pulse schreibt ein User, daß er am Freitag ein "stock halted" auf dem Nasdaq Bookviewer (?) gesehen hat. Aber noch mehr bewegen das gesteigerte Aktienvolumen und die positiven Chartanalysen die Gemüter. Es könnte wirklich was im Busch sein. Hoffen wir das Beste. biotech
Auf YaFi's Market Pulse schreibt ein User, daß er am Freitag ein "stock halted" auf dem Nasdaq Bookviewer (?) gesehen hat. Aber noch mehr bewegen das gesteigerte Aktienvolumen und die positiven Chartanalysen die Gemüter. Es könnte wirklich was im Busch sein. Hoffen wir das Beste. biotech
Viele meiner Favoriten im Keller. Dynavax habe ich verkauft und bin komplett bei NWBO rein. Keine Amarin (puh, schwitz), keine Ariad, keine Galena, keine Mannkind, keine Merrimack, keine Chelsea und (leider) keine Cytrix. Ich denke, für eine lange Position sind die DAVX immer noch super zu haben. Es hätte ja ich etwas kommen können über das Wochenende. Die Zeichen standen ja gut. Ansonsten immer noch bei MNKD ein Auge drauf. Und nicht zu vergessen: Novavax. Steht im DVAX Artikel von Seeking Alpha mit drin. Diese Woche eventuell noch eine Meldung von PharmAthene, da wird eine FDA-Antwort zum Trial-Stop erwartet. Außerdem für diese/nächste Woche: IntelGenx PDUFA-Date. biotech